Cargando…

MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas

The monoclonal antibody G250 (mAbG250) raised against a human renal cell carcinoma (RCC) has been shown to react with a large number of RCCs. Recently, G250 antigen was isolated and found to be homologous to the MN/CA9 gene originally identified in HeLa cells. To determine whether G250 antigen (MN/C...

Descripción completa

Detalles Bibliográficos
Autores principales: Uemura, H, Nakagawa, Y, Yoshida, K, Saga, S, Yoshikawa, K, Hirao, Y, Oosterwijk, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362900/
https://www.ncbi.nlm.nih.gov/pubmed/10574265
http://dx.doi.org/10.1038/sj.bjc.6690757
_version_ 1782153569383743488
author Uemura, H
Nakagawa, Y
Yoshida, K
Saga, S
Yoshikawa, K
Hirao, Y
Oosterwijk, E
author_facet Uemura, H
Nakagawa, Y
Yoshida, K
Saga, S
Yoshikawa, K
Hirao, Y
Oosterwijk, E
author_sort Uemura, H
collection PubMed
description The monoclonal antibody G250 (mAbG250) raised against a human renal cell carcinoma (RCC) has been shown to react with a large number of RCCs. Recently, G250 antigen was isolated and found to be homologous to the MN/CA9 gene originally identified in HeLa cells. To determine whether G250 antigen (MN/CA IX/G250) could be a potential therapeutic target and a tumour marker, a total of 147 cases of RCC were investigated immunohistochemically as well as by reverse transcriptase polymerase chain reaction (RT-PCR) analysis. In addition, total RNAs extracted from patients' peripheral blood samples were analysed for MN/CA9/G250 mRNA signals. Immunohistochemistry demonstrated strong expression in 128/147 (87.1%) of RCCs, in contrast to the lack of expression observed in normal tissues. RT-PCR analyses of frozen specimens resulted in the clear detection of MN/CA9/G250 mRNA signals in 137/147 (93.2%), and despite subtle differences the results were almost identical to those for immunohistochemistry. Although high-grade and -stage tumours exhibited significantly lower expression than low-grade and -stage tumours, a large proportion of tumours expressed MN/G250 protein as well as mRNA. RT-PCR analysis of patients' blood samples revealed the presence of circulating MN/CA9/G250 expressing cells. These findings suggest that this antigen may be a potential therapeutic target as well as diagnostic marker for RCCs. © 1999 Cancer Research Campaign
format Text
id pubmed-2362900
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23629002009-09-10 MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas Uemura, H Nakagawa, Y Yoshida, K Saga, S Yoshikawa, K Hirao, Y Oosterwijk, E Br J Cancer Regular Article The monoclonal antibody G250 (mAbG250) raised against a human renal cell carcinoma (RCC) has been shown to react with a large number of RCCs. Recently, G250 antigen was isolated and found to be homologous to the MN/CA9 gene originally identified in HeLa cells. To determine whether G250 antigen (MN/CA IX/G250) could be a potential therapeutic target and a tumour marker, a total of 147 cases of RCC were investigated immunohistochemically as well as by reverse transcriptase polymerase chain reaction (RT-PCR) analysis. In addition, total RNAs extracted from patients' peripheral blood samples were analysed for MN/CA9/G250 mRNA signals. Immunohistochemistry demonstrated strong expression in 128/147 (87.1%) of RCCs, in contrast to the lack of expression observed in normal tissues. RT-PCR analyses of frozen specimens resulted in the clear detection of MN/CA9/G250 mRNA signals in 137/147 (93.2%), and despite subtle differences the results were almost identical to those for immunohistochemistry. Although high-grade and -stage tumours exhibited significantly lower expression than low-grade and -stage tumours, a large proportion of tumours expressed MN/G250 protein as well as mRNA. RT-PCR analysis of patients' blood samples revealed the presence of circulating MN/CA9/G250 expressing cells. These findings suggest that this antigen may be a potential therapeutic target as well as diagnostic marker for RCCs. © 1999 Cancer Research Campaign Nature Publishing Group 1999-10 /pmc/articles/PMC2362900/ /pubmed/10574265 http://dx.doi.org/10.1038/sj.bjc.6690757 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Uemura, H
Nakagawa, Y
Yoshida, K
Saga, S
Yoshikawa, K
Hirao, Y
Oosterwijk, E
MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas
title MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas
title_full MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas
title_fullStr MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas
title_full_unstemmed MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas
title_short MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas
title_sort mn/ca ix/g250 as a potential target for immunotherapy of renal cell carcinomas
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362900/
https://www.ncbi.nlm.nih.gov/pubmed/10574265
http://dx.doi.org/10.1038/sj.bjc.6690757
work_keys_str_mv AT uemurah mncaixg250asapotentialtargetforimmunotherapyofrenalcellcarcinomas
AT nakagaway mncaixg250asapotentialtargetforimmunotherapyofrenalcellcarcinomas
AT yoshidak mncaixg250asapotentialtargetforimmunotherapyofrenalcellcarcinomas
AT sagas mncaixg250asapotentialtargetforimmunotherapyofrenalcellcarcinomas
AT yoshikawak mncaixg250asapotentialtargetforimmunotherapyofrenalcellcarcinomas
AT hiraoy mncaixg250asapotentialtargetforimmunotherapyofrenalcellcarcinomas
AT oosterwijke mncaixg250asapotentialtargetforimmunotherapyofrenalcellcarcinomas